Clinical success of LOW LEVEL LASER THERAPY to treat FMS reported in Fibromyalgia Aware

NewsGuard 100/100 Score

Fibromyalgia is a condition in which the brain processes pain in an abnormal way, resulting in chronic, widespread muscular-skeletal pain and chronic fatigue. This condition effects millions of Americans and has been poorly understood and under diagnosed, resulting in billions of dollars in cost to our health care system. In the past, treatments have been primarily with medications; often side effects can make the symptoms worse.

The Laser is the Patented ML830 which was the first "LOW LEVEL LASER" approved by the FDA in 2002 to treat pain and swelling. The Laser produces no heat to the tissue and causes vassal dilation in the Micro Capillary bed, the treatment is PAINLESS WITH NO SIDE EFFECTS. Bernard Filner M.D. is now reporting on treating over 90,000 Fibro Trigger Points using the ML830 Laser with a 90% success rate.

Bernard Filner, M.D. reports his clinical success in the use of LOW LEVEL LASER THERAPY to treat FIBROMYALGIA SYNDROME (FMS) in the April 2010 issue of Fibromyalgia Aware (the quarterly journal of the National Fibromyalgia Association) Dr. Filner sits on the National Advisory Board. Dr. Filner has been in the forefront of the practice of Pain Management for the past 22 years, (specializing in the treatment of MYOFASCIAL PAIN and FIBROMYALGIA) and an anesthesiologist for the prior 18 years (CV available upon request).

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Depression linked to chronic pain: Variability shown across patient characteristics